Leveraging Vγ9Vδ2 T cells against prostate cancer through a VHH-based PSMA-Vδ2 bispecific T cell engager

Lisa A. King(Leiden University Medical Center)

iScience

October 31, 2024

10.1016/j.isci.2024.111289

Cited by 5

Related Papers

A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell–Mediated Immune Response against EGFR-Expressing Tumors

|Cancer Immunology Research|2023|35

PD-L1 directed bispecific Vδ2-T cell engager combines lysis of PD-L1 expressing tumor cells with PD-1 immune checkpoint inhibition and modulation of the tumor immune microenvironment

|Journal for ImmunoTherapy of Cancer|2025|3

Vδ2 T-cell engagers bivalent for Vδ2-TCR binding provide anti-tumor immunity and support robust Vγ9Vδ2 T-cell expansion

|Frontiers in Oncology|2024|2